Christopher Marshall, DO
Nephrology · Winston Salem, NCNPI 1700197266
Payments from drug & device makers
Across 467 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$794
- Vifor Pharma, Inc.$696
- Mallinckrodt Hospital Products Inc.$615
- Novartis$612
- plus $4K from 28 others
What the payments were for
- Food & beverage$8,77896%
- Education$3624%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 61 | $1,252 |
| AstraZeneca(2 entities) | 70 | $1,234 |
| Otsuka America Pharmaceutical, Inc. | 34 | $794 |
| Vifor Pharma, Inc. | 30 | $696 |
| Mallinckrodt Hospital Products Inc. | 28 | $615 |
| Novartis | 39 | $612 |
| Aurinia Pharma U.S., Inc. | 19 | $536 |
| Travere Therapeutics, Inc. | 19 | $398 |
| Bayer | 20 | $349 |
| Novo Nordisk | 18 | $314 |
| Boehringer Ingelheim | 17 | $298 |
| Akebia Therapeutics Inc | 17 | $268 |
| Mallinckrodt Enterprises LLC | 8 | $230 |
| ANI Pharmaceuticals, Inc. | 13 | $199 |
| GSK | 11 | $188 |
| OPKO Pharmaceuticals, LLC | 11 | $184 |
| Daiichi Sankyo Inc. | 7 | $158 |
| Fresenius USA Marketing, Inc. | 7 | $117 |
| Calliditas Therapeutics US Inc. | 4 | $84 |
| Shield Therapeutics Inc | 5 | $81 |
| Shire North American Group Inc | 5 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Ardelyx, Inc. | 4 | $65 |
| Lilly USA, LLC | 3 | $50 |
| Scpharmaceuticals Inc. | 2 | $41 |
| Argenx US, Inc. | 2 | $38 |
| Rockwell Medical, Inc. | 2 | $36 |
| Apellis Pharmaceuticals, Inc. | 2 | $34 |
| Outset Medical Inc | 1 | $24 |
| Baxter Healthcare | 1 | $22 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
How this compares
$9,140 in reported general payments places this provider in the 75th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 127 | $102,170 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $28,626 |
| VeltassaPatiromer Calcium Sorbitex | 17 | $24,318 |
| JardianceEmpagliflozin | 37 | $23,410 |
| Sevelamer Carbonate | 47 | $8,140 |
| Calcium Acetate | 15 | $2,097 |
| Mycophenolate Mofetil | 23 | $1,537 |
| Febuxostat | 11 | $1,500 |
| Allopurinol | 136 | $1,282 |
| Furosemide | 239 | $1,277 |
| Lisinopril | 130 | $1,112 |
| Hydralazine Hcl | 63 | $972 |
| Amlodipine Besylate | 171 | $943 |
| Losartan Potassium | 69 | $835 |
| Metoprolol Succinate | 34 | $802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,234 | $130,796160 claims |
| Boehringer IngelheimJardiance | $298 | $23,41037 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $199 | $43118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Winston Salem
- Barry FreedmanWinston Salem$3.5M
- Michael RoccoWinston Salem$660K
- Nicholas McLeanWinston Salem$215K
- Scott SatkoWinston Salem$95K
- Anthony BleyerWinston Salem$71K
- Mariana MureaWinston Salem$36K
- Taewoo LeeWinston Salem$27K
- Daniel EdmonstonDurham$9.9M
- Gregory GreenwoodWinston-Salem$4.1M
- Manuel MonteroNew Bern$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.